Dynamic bio-nanoparticle platforms
The invention in suitable embodiments is directed to dynamic bio-nanoparticle elements and bio-nanoparticle platforms employing such bio-nanoparticle elements. In one aspect, one or more elements of one or more types, formed from isolated, synthetic and or recombinant amino acid residues comprising in whole or in part one or more types of Clathrin and or Coatomer I/II proteins of one or more isoforms, execute one or more functions and or effect one or more ends, in vivo and or in vitro.
1. A nanoparticle comprising a clathrin triskelion linked to (a) a cargo selected from the group consisting of a therapeutic or diagnostic agent or a targeting moiety, and (b) a masking moiety, wherein the clathrin triskelion comprises three human clathrin heavy chains of SEQ ID NO:1, and wherein the masking moiety is polyethylene glycol, surfactant, or cosurfactant.
2. The nanoparticle of claim 1 , wherein the therapeutic or diagnostic agent is a growth factor, imaging contrast agent, imaging tracer agent, radiodiagnostic agent, nucleic acid, oligonucleotide, peptide, carbohydrate, phospholipid, antineoplastic agent, metal, chemical, vaccine, vitamin, hormone, antibiotic, or antibody.
3. A nanoparticle comprising a clathrin triskelion covalently linked to a cargo selected from the group consisting of a therapeutic or diagnostic agent, a targeting moiety, and a masking moiety, wherein the clathrin triskelion comprises three human clathrin heavy chains of SEQ ID NO:1, and wherein the targeting moiety is an antibody, peptide, fluorophore, permeation enhancer, amino sugar, lipoprotein, toxin, transferrin, or glycoprotein.
4. The nanoparticle of claim 3 , wherein the fluorophore is excitable by an infrared, visible, or ultraviolet light.
5. The nanoparticle of claim 2 , wherein the imaging contrast agent comprises a gadolinium-based contrast agent, magnetic iron oxide, or manganese-based contrast agent.
6. The nanoparticle of claim 5 , wherein the gadolinium-based contrast agent comprises a chelating agent selected from the group consisting of: Diethylene triamine pentaacetic acid (DTPA), 1,4,7,10-Tetraazacyclododecane-1,4,7-triacetic acid trisodium salt (DO3A), and 1,4,7,10-Tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA).
7. The nanoparticle of claim 2 , wherein the growth factor comprises epidermal growth factor, transforming growth factor a (TGFa), nerve growth factor, neurotrophic factor, or platelet derived growth factor.
8. The nanoparticle of claim 2 , wherein the nucleic acid is an mRNA, RNAi, siRNA, RNA-induced silencing complex (RISC), or DNA.
9. The nanoparticle of claim 2 , wherein the hormone comprises insulin, thyroid stimulating hormone, thyroid hormone, growth hormone, calcitonin, glucagon, prolactin, or Luteinizing Hormone.
10. The nanoparticle of claim 2 , wherein the antibody is a monoclonal antibody.
11. The nanoparticle of claim 1 , wherein at least one of the human clathrin heavy chains of SEQ ID NO: 1 is linked to the cargo.
12. The nanoparticle of claim 11 , wherein the human clathrin heavy chain of SEQ ID NO: 1 is linked to the cargo via biotin-avidin interaction, PEGylation, cross-linking, molecular tether, non-covalent or covalent bonding.
13. A nanoparticle comprising a clathrin triskelion linked to a cargo selected from the group consisting of a therapeutic or diagnostic agent, a targeting moiety, and a masking moiety, wherein the clathrin triskelion comprises three human clathrin heavy chains of SEQ ID NO:1, and wherein at least one of the human clathrin heavy chains of SEQ ID NO: 1 forms a fusion protein with the cargo.
14. The nanoparticle of claim 13 , wherein the therapeutic or diagnostic agent is a growth factor, peptide, hormone, antibody, lipoprotein, or glycoprotein.
15. The nanoparticle of claim 14 , wherein the growth factor comprises epidermal growth factor, transforming growth factor a (TGFa), nerve growth factor, neurotrophic factor, or platelet derived growth factor.
16. The nanoparticle of claim 14 , wherein the hormone comprises insulin, thyroid stimulating hormone, thyroid hormone, growth hormone, calcitonin, glucagon, prolactin, or Luteinizing Hormone.
17. The nanoparticle of claim 14 , wherein the antibody is a monoclonal antibody.
18. The nanoparticle of claim 1 , wherein the nanoparticle is not linked to a targeting moiety.
19. The nanoparticle of claim 1 , wherein one or more of the human clathrin heavy chain is further linked to one human clathrin light chain.